Previous 10 | Next 10 |
Los Angeles, CA, Nov. 19, 2019 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), announced today its financial results for the quarter ended September 30, 2019. Key Financial Highlights: Revenues for the three months ended September 30, 2019...
ENDV has developed a viable pain-control solution for those seeking alternatives to highly addictive opioids The company’s flagship product is an FDA-cleared, easy-to-place, noninvasive device that delivers pulsed electromagnetic frequencies to targeted area In one study, patient...
Commercial-stage developer of innovative medical devices Endonovo Therapeutics (OTCQB: ENDV) was recently featured in a Wect.com article by Jack Bailey titled, ‘Medical device lowers opioid prescriptions at NHRMC’. The article highlights ENDV’s noninvasive Electroceuti...
Commercial-stage developer of innovative medical devices Endonovo Therapeutics (OTCQB: ENDV) recently named Dr. William Li, CEO and co-founder of the Angiogenesis Foundation, as a strategic advisor to the CEO. An article discussing the company reads, “The role of Li would be to strate...
Endonovo Therapeutics (OTCQB: ENDV) , a commercial-stage developer of noninvasive Electroceutical(R) therapeutic devices, on Thursday announced its filing of a preliminary information statement with respect to a proposed reverse stock split of its common stock at a ratio of between 1 for 100 ...
Los Angeles, CA, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today announced that it had filed a preliminary information statement with respect to a proposed a reverse stock split of its common stock at a ratio of between 1...
Endonovo Therapeutics’ (OTCQB: ENDV) proprietary SofPulse(R) flagship device recently received a glowing review for minimizing pain from a foot-and-ankle specialist in Ohio who underwent tendon surgery. An article discussing the company reads, “In a homemade video, Dr. Jane Gra...
The new strategic advisor, Dr. William Li, is a globally recognized medical professional One of Li’s primary specialties is the identification of unmet medical market needs that can be addressed through technological advances Endonovo is working to develop solutions for major the...
Endonovo Therapeutics (OTCQB: ENDV) , a commercial-stage developer of noninvasive Electroceutical® therapeutic devices, has completed clinical trials and is currently expanding commercialization of its SofPulse® device that delivers pulsed electromagnetic frequencies for pain manage...
Endonovo Therapeutics is developing a bioceutical device that provides an alternative to the prescription pain pills blamed for hundreds of thousands of deaths in recent years as part of a multinational opioid crisis Endonovo’s proprietary SofPulse® flagship device provides an...
News, Short Squeeze, Breakout and More Instantly...
Endonovo Therapeutics Inc Company Name:
ENDV Stock Symbol:
OTCMKTS Market:
Endonovo Therapeutics Inc Website:
ADDvantage Technologies Group Inc. (AEYGQ) is expected to report for Q1 2024 ContraFect Corporation (CFRXQ) is expected to report for Q1 2024 American Clean Resources Group Inc (ACRG) is expected to report for Q1 2024 Atlantic Lithium Ltd Ord Fully Paid (ALLIF) is expected to report f...
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...
Gelesis Holdings, Inc. (GLSHQ) is expected to report for Q1 2024 EVmo Inc (YAYO) is expected to report for Q1 2024 Chiba Bank Ltd. ADR (CHBAY) is expected to report for Q4 2024 Spark Networks SE (LOVLQ) is expected to report for Q1 2024 ToughBuilt Industries Inc. (TBLT) is expecte...